Novavax Inc. closed 60.86% short of its 52-week high of $17.81, which the company reached on July 26th.

A new Covid-19 vaccine from Novavax was found to be 89.3% effective in a clinical trial conducted in the UK and appears to offer protection against some variants of the coronavirus, the American ...

Novavax to partner with FUJIFILM Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in the UK Novavax and UK government to collaborate on Phase 3 clinical trial in UK ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

In the closing of the recent trading day, Novavax (NVAX) stood at $6.97, denoting a +1.9% move from the preceding trading day.

The UK government will collaborate with Novavax on phase 3 trials of its NVX-CoV2373 vaccine, according to a press release.

Novavax’s COVID-19 vaccine shown to be nearly 90% effective in UK clinical trial, provided a range of immunity against new variants ...

Novavax Inc (NVAX.O) said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting ...

Novavax said Thursday that final data from a trial in the United Kingdom shows its COVID-19 vaccine is almost 90 percent effective, but the vaccine was far less effective in a separate trial in Sou… ...

Biotech firm Novavax has labs in the US (pictured) and has carried out trials in the UK and South Africa A new coronavirus vaccine has been shown to be 89% effective in large-scale UK trials. The ...

Novavax on Thursday said that its vaccine was 89% effective at preventing cases of COVID-19, based on results from a UK trial. In a trial in South Africa, the vaccine was far less effective ...

Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new ...